Delta Global Management LP Invests $1.89 Million in Edwards Lifesciences Corporation $EW

Delta Global Management LP bought a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) in the 4th quarter, Holdings Channel.com reports. The institutional investor bought 22,175 shares of the medical research company’s stock, valued at approximately $1,890,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Vanguard Group Inc. boosted its stake in shares of Edwards Lifesciences by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 70,363,210 shares of the medical research company’s stock worth $5,472,147,000 after acquiring an additional 365,581 shares during the period. State Street Corp boosted its stake in shares of Edwards Lifesciences by 1.5% during the 4th quarter. State Street Corp now owns 25,991,524 shares of the medical research company’s stock worth $2,215,777,000 after acquiring an additional 371,892 shares during the period. Wellington Management Group LLP boosted its stake in shares of Edwards Lifesciences by 4.9% during the 3rd quarter. Wellington Management Group LLP now owns 20,804,416 shares of the medical research company’s stock worth $1,617,959,000 after acquiring an additional 977,933 shares during the period. Norges Bank bought a new position in shares of Edwards Lifesciences during the 4th quarter worth approximately $803,686,000. Finally, Morgan Stanley boosted its stake in shares of Edwards Lifesciences by 12.4% during the 4th quarter. Morgan Stanley now owns 7,314,292 shares of the medical research company’s stock worth $623,544,000 after acquiring an additional 804,942 shares during the period. 79.46% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms recently weighed in on EW. Evercore reissued an “outperform” rating and set a $93.00 price target on shares of Edwards Lifesciences in a report on Friday, April 24th. Royal Bank Of Canada reissued an “outperform” rating and set a $100.00 price target on shares of Edwards Lifesciences in a report on Tuesday. Canaccord Genuity Group set a $85.00 price target on Edwards Lifesciences and gave the stock a “hold” rating in a report on Friday, April 24th. Truist Financial set a $90.00 price target on Edwards Lifesciences and gave the stock a “hold” rating in a report on Friday, April 24th. Finally, BTIG Research lifted their price target on Edwards Lifesciences from $98.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, April 24th. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $95.96.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $88.56 on Wednesday. The stock has a market cap of $51.00 billion, a P/E ratio of 47.11, a PEG ratio of 2.16 and a beta of 0.87. The stock has a 50 day simple moving average of $83.03 and a 200 day simple moving average of $83.11. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 1-year low of $72.30 and a 1-year high of $89.60.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.73 by $0.05. The business had revenue of $1.65 billion during the quarter, compared to analysts’ expectations of $1.60 billion. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The firm’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same period last year, the firm posted $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Research analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Insider Buying and Selling

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $80.04, for a total value of $1,040,520.00. Following the completion of the transaction, the chief financial officer directly owned 39,699 shares of the company’s stock, valued at $3,177,507.96. The trade was a 24.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Daniel J. Lippis sold 1,019 shares of Edwards Lifesciences stock in a transaction on Friday, May 1st. The shares were sold at an average price of $83.01, for a total value of $84,587.19. Following the completion of the transaction, the vice president directly owned 33,934 shares of the company’s stock, valued at $2,816,861.34. This represents a 2.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 81,038 shares of company stock valued at $6,683,255 over the last 90 days. 0.31% of the stock is currently owned by insiders.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.